Literature DB >> 22697084

Acquired peripheral neuropathy: a report on 20 children.

P Pavone, A D Praticò, M Ruggieri, A Verrotti, D Castellano-Chiodo, F Greco, R Falsaperla, L Pavone.   

Abstract

Guillain-Barré syndrome (GBS) is an inflammatory polyneuropathy characterized by acute onset, rapid progression, symmetric muscular weakness, pain, and paresthesias. The incidence of GBS in the pediatric age group is 0.8 cases per 100,000; 50%-70% of the cases are preceded by respiratory or gastrointestinal infectious episodes or vaccination. The etiopathogenesis of GBS has been hypothesized to involve a direct immune-mediated mechanism against the peripheral nerves. A series of 20 patients managed in the Department of Pediatrics of the University of Catania between 2003 and 2011 and evaluated according to epidemiologic, clinical, and therapeutic features is reported.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22697084     DOI: 10.1177/039463201202500222

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  3 in total

1.  Hereditary neuropathy with liability to pressure palsies (HNPP): Intrafamilial phenotypic variability and early childhood refusal to walk as the presenting symptom.

Authors:  Shani Karklinsky; Shir Kugler; Omer Bar-Yosef; Andreea Nissenkorn; Anat Grossman-Jonish; Irit Tirosh; Asaf Vivante; Ben Pode-Shakked
Journal:  Ital J Pediatr       Date:  2022-06-03       Impact factor: 3.288

Review 2.  Ataxia in children: early recognition and clinical evaluation.

Authors:  Piero Pavone; Andrea D Praticò; Vito Pavone; Riccardo Lubrano; Raffaele Falsaperla; Renata Rizzo; Martino Ruggieri
Journal:  Ital J Pediatr       Date:  2017-01-13       Impact factor: 2.638

Review 3.  Ptosis in childhood: A clinical sign of several disorders: Case series reports and literature review.

Authors:  P Pavone; Sung Yoon Cho; A D Praticò; R Falsaperla; M Ruggieri; Dong-Kyu Jin
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.